

Health Program & Insurance Guide for the BIOFIRE® SPOTFIRE® Respiratory Sore Throat (R/ST) Panel

bioMérieux developed the following Health Program & Insurance guide for healthcare providers who administer the BIOFIRE® SPOTFIRE® Respiratory Sore Throat (R/ST) Panel (SPOTFIRE R/ST Panel), which is FDA-cleared. We describe below our current understanding of the coverage, coding, and payment for administering the BIOFIRE® SPOTFIRE® Respiratory Sore Throat (R/ST) Panel as of: June 14, 2024.

About the BIOFIRE SPOTFIRE Respiratory Sore Throat (R/ST) Panel

The BIOFIRE® SPOTFIRE® Respiratory Sore Throat (R/ST) Panel (SPOTFIRE R/ST Panel) is a multiplexed polymerase chain reaction (PCR) test intended for use with the BIOFIRE® SPOTFIRE® System for the simultaneous, qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections, including COVID-19; (Respiratory menu) or in throat swab (TS) specimens from individuals with signs and symptoms of pharyngitis (Sore Throat menu).

The user can choose to perform Respiratory targets **or** Sore Throat targets. The following targets are performed based on the selection:

Respiratory Menu	Sore Throat Menu
Viruses	Viruses
Adenovirus	Adenovirus
Coronavirus SARS-CoV-2	Coronavirus (seasonal)
Coronavirus (seasonal)	Human metapneumovirus
Human metapneumovirus	Human rhinovirus/enterovirus
Human rhinovirus/enterovirus	Influenza A virus
Influenza A virus	Influenza A virus/H1-2009
Influenza A virus/H1-2009	Influenza A virus/H3
Influenza A virus/H3	Influenza B virus
Influenza B virus	Parainfluenza virus
Parainfluenza virus	Respiratory syncytial virus
Respiratory syncytial virus	
Bacteria	Bacteria
<i>Bordetella parapertussis</i>	<i>Chlamydia pneumoniae</i>
<i>Bordetella pertussis</i>	<i>Mycoplasma pneumoniae</i>
<i>Chlamydia pneumoniae</i>	<i>Streptococcus dysgalactiae</i> (Group C/G Strep)
<i>Mycoplasma pneumoniae</i>	<i>Streptococcus pyogenes</i> (Group A Strep)

Based on currently available information, the BIOFIRE® SPOTFIRE® Respiratory Sore Throat (R/ST) Panel may be described by the following CPT code(s) based on the specific panel selected for testing:

Applicable Code(s) for Respiratory Panel Targets

CPT code 87632 – Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets

If the practice/lab running the test has a CLIA Certificate of Waiver, a QW modifier is required.

AND

CPT code 87486 – Infectious agent detection by nucleic acid (DNA or RNA); *Chlamydia pneumoniae*, amplified probe technique

AND

CPT code 87581 – Infectious agent detection by nucleic acid (DNA or RNA); *Mycoplasma pneumoniae*, amplified probe technique

AND

CPT code 87798 – Infectious agent detection by nucleic acid (DNA or RNA); not otherwise specified, amplified probe technique

This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Note that payers that follow NCCI guidance may recommend the use of alternate code(s). It is always the provider's responsibility to determine and submit appropriate codes for services that are rendered, consistent with applicable payer guidance. bioMérieux recommends that you consult with your payer, reimbursement specialist and/or legal counsel regarding coding, coverage, and reimbursement matters. Payer coding, coverage, and reimbursement policies may vary and should be verified prior to claim submission. *This information is gathered from third-party sources and is subject to change without notice, including as a result of changes in laws, regulations, rules, and policies. BFR0002-8506-01*

Applicable Code(s) for Sore Throat Panel Targets

CPT 87632 -- Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets

If the practice/lab running the test has a CLIA Certificate of Waiver, a QW modifier is required.

AND

CPT 87486 – Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique

AND

CPT 87581 – Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, amplified probe technique

AND

CPT 87798 – Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism

AND

CPT 87651 – Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique

Coverage

Coverage is a payer's determination that items and services are medically necessary for a patient and may be included under the patient's health insurance benefits. Coverage varies by payer. Healthcare providers should consult with individual payers regarding their coverage policies, including any applicable coverage criteria or documentation requirements.

For more information on Medicare and select state Medicaid programs' coverage of the BIOFIRE® SPOTFIRE® Respiratory Sore Throat (R/ST) Panel please consult CodeMap at: <http://www.codemap.com/biofire>.

Coding

Coding enables healthcare providers to communicate to payers the items and services furnished to a patient in order to obtain payment for those items and services. It is the sole responsibility of the healthcare provider to determine the most appropriate codes to report on a claim, upon consultation of specific payer policies.

Payment

Payment is the amount a payer renders to a healthcare provider for furnishing items and services to a patient. Patients may also have cost-sharing obligations, including deductibles, coinsurance or copayments, depending on their health insurance benefits. Payment amounts vary by payer and by geographic location, and are frequently updated, but are generally an allowable amount minus any patient cost-sharing amount. Healthcare providers should consult with individual payers regarding applicable current allowable amounts.

For more information on Medicare and select state Medicaid programs' allowable rates for the BIOFIRE® SPOTFIRE® Respiratory Sore Throat (R/ST) Panel, please consult CodeMap at: <http://www.codemap.com/biofire>. Medicare rate limits can also be found on the CMS website within the Clinical Laboratory Fee Schedule (CLFS) section; the CLFS is updated annually.

References:

[K232954 \(fda.gov\)](https://www.fda.gov/oc/2014/01/k232954)

This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Note that payers that follow NCCI guidance may recommend the use of alternate code(s). It is always the provider's responsibility to determine and submit appropriate codes for services that are rendered, consistent with applicable payer guidance. bioMerieux recommends that you consult with your payer, reimbursement specialist and/or legal counsel regarding coding, coverage, and reimbursement matters. Payer coding, coverage, and reimbursement policies may vary and should be verified prior to claim submission. *This information is gathered from third-party sources and is subject to change without notice, including as a result of changes in laws, regulations, rules, and policies. BFR0002-8506-01*

CPT® copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.